{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:39:55Z","timestamp":1784637595943,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BE1967\/5-1"],"award-info":[{"award-number":["BE1967\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113911","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T15:54:54Z","timestamp":1633967694000},"page":"113911","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/\u03b1-synuclein aggregation inhibitors with neuroprotective effects"],"prefix":"10.1016","volume":"227","author":[{"given":"Yasmeen T.","family":"AlNajjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed K.","family":"ElHady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-6741","authenticated-orcid":false,"given":"Mohamed","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-0172","authenticated-orcid":false,"given":"Gerrit","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf H.","family":"Abadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-4768","authenticated-orcid":false,"given":"Walter","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-4219","authenticated-orcid":false,"given":"Mohammad","family":"Abdel-Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Engel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113911_bib1","article-title":"DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis","author":"Laham","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2021.113911_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph12040185","article-title":"Biological characterization of 8-cyclopropyl-2-(Pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8h)-one, a promising inhibitor of DYRK1A","volume":"12","author":"Fruit","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2021.113911_bib3","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.bbapap.2013.02.001","article-title":"Identification and characterization of bi-thiazole-2,2\u2032-diamines as kinase inhibitory scaffolds","volume":"1834","author":"Ngoei","year":"2013","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"key":"10.1016\/j.ejmech.2021.113911_bib4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.celrep.2013.03.027","article-title":"The protein interaction landscape of the human CMGC kinase group","volume":"3","author":"Varjosalo","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2021.113911_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.str.2013.03.012","article-title":"Structures of down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition","volume":"21","author":"Soundararajan","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.113911_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pharmthera.2018.09.010","article-title":"DYRK1A and cognition: a lifelong relationship","volume":"194","author":"Arbones","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113911_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.mcn.2007.07.007","article-title":"Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome","volume":"36","author":"Park","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1096\/fj.10-165837","article-title":"DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles","volume":"25","author":"Aranda","year":"2011","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2021.113911_bib9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ajmg.a.33228","article-title":"Microdeletion of the Down syndrome critical region at 21q22","volume":"152","author":"Fujita","year":"2010","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2021.113911_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041404","article-title":"Molecular rescue of DYRK1A overexpression alterations in mice with fontup\u00ae dietary supplement: role of green tea catechins","volume":"21","author":"Gu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113911_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2005.02.004","article-title":"Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+\/- mouse","volume":"20","author":"Benavides-Piccione","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2021.113911_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/brainsci8100187","article-title":"DYRK1A protein, a promising therapeutic target to improve cognitive deficits in down syndrome","volume":"8","author":"Feki","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejmech.2021.113911_bib13","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.1007\/s12035-019-01684-9","article-title":"Chronic Dyrk1 inhibition delays the onset of AD-like pathology in 3xTg-AD mice","volume":"56","author":"Velazquez","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113911_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/cn300094k","article-title":"Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimers?","volume":"3","author":"Smith","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-019-0678-6","article-title":"Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP\/PS1 mice","volume":"7","author":"Souchet","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ejmech.2021.113911_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000356529","article-title":"Innate immune system and inflammation in Alzheimer's disease: from pathogenesis to treatment","volume":"21","author":"Serpente","year":"2014","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.ejmech.2021.113911_bib17","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau: a functional link between down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2019.134541","article-title":"microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing","volume":"714","author":"Chaves","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.113911_bib19","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","article-title":"Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease","volume":"104","author":"Ryoo","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113911_bib20","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/acsmedchemlett.0c00346","article-title":"Selective DYRK1A inhibitor for the treatment of neurodegenerative diseases: alzheimer, Parkinson, Huntington, and down syndrome","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113911_bib21","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acschemneuro.0c00281","article-title":"Dual targeting of monomeric tau and \u03b1-synuclein aggregation: a new multitarget therapeutic strategy for neurodegeneration","volume":"11","author":"Gabr","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib22","series-title":"Emerging Urinary Alpha-Synuclein and miRNA Biomarkers in Parkinson \u2019 S Disease","author":"Giri","year":"2021"},{"key":"10.1016\/j.ejmech.2021.113911_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnmol.2019.00107","article-title":"Spreading of \u03b1-synuclein and tau: a systematic comparison of the mechanisms involved","volume":"12","author":"Vasili","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib24","series-title":"Understanding the multifaceted role of human down syndrome kinase DYRK1A","author":"Kay","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113911_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neulet.2016.08.022","article-title":"Association of DYRK1A polymorphisms with sporadic Parkinson's disease in Chinese Han population","volume":"632","author":"Cen","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.113911_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000334759","article-title":"A\u00a0pilot study examining associations between DYRK1A and \u03b1-synuclein dementias","volume":"10","author":"Jones","year":"2012","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ejmech.2021.113911_bib27","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.neuroscience.2008.09.034","article-title":"The down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4","volume":"157","author":"Sitz","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejmech.2021.113911_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2018.00029","article-title":"A\u00a0comprehensive atlas of E3 ubiquitin ligase mutations in neurological disorders","volume":"9","author":"George","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.ejmech.2021.113911_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2018.08.097","article-title":"Development of novel amide\u2013derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: identification of the cyclopropylamide moiety as a key modification","volume":"158","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmgm.2017.01.014","article-title":"Multi-step virtual screening to develop selective DYRK1A inhibitors","volume":"72","author":"Koyama","year":"2017","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2021.113911_bib31","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","article-title":"Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B","volume":"55","author":"Tahtouh","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib32","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib33","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1021\/acs.jmedchem.9b01624","article-title":"Selective DYRK1A inhibitor for the treatment of type 1 diabetes: discovery of 6-azaindole derivative GNF2133","volume":"63","author":"Liu","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib34","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejmech.2018.07.050","article-title":"Development of novel 2,4-bispyridyl thiophene\u2013based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives","volume":"157","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib35","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1039\/C8MD00142A","article-title":"Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core","volume":"9","author":"Salah","year":"2018","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2021.113911_bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","article-title":"Multi-target design strategies for the improved treatment of Alzheimer's disease","volume":"176","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/ecp.11.13","article-title":"The use of multi-target drugs in the treatment of neurodegenerative diseases","volume":"4","author":"Van Der Schyf","year":"2011","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113911_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1673-5374.245463","article-title":"Multitarget therapeutic strategies for Alzheimer's disease","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.ejmech.2021.113911_bib39","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1021\/acs.jmedchem.6b01086","article-title":"Probing the ATP-binding pocket of protein kinase DYRK1A with benzothiazole fragment molecules","volume":"59","author":"Rothweiler","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087851","article-title":"Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective dyrk\/Clk inhibitors","volume":"9","author":"Schmitt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113911_bib41","series-title":"Selectivity profiling and biological activity of novel \u03b2 -Carbolines as potent and selective DYRK1 kinase inhibitors","first-page":"1","author":"R\u00fcben","year":"2015"},{"key":"10.1016\/j.ejmech.2021.113911_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113911_bib43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/ml500059y","article-title":"Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1\/4","volume":"5","author":"Schmitt","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113911_bib44","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/jm200274d","article-title":"Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing","volume":"54","author":"Debdab","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2012.11.030","article-title":"Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d] pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases","volume":"59","author":"Loidreau","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib46","first-page":"1347","volume":"27","author":"Deshmukh","year":"2019"},{"key":"10.1016\/j.ejmech.2021.113911_bib47","series-title":"Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay","volume":"84","author":"Martinez","year":"2014"},{"key":"10.1016\/j.ejmech.2021.113911_bib48","first-page":"1","article-title":"A\u00a0widely-applicable high- throughput cellular thermal shift assay (CETSA) using split Nano Luciferase","author":"Martinez","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113911_bib49","series-title":"SF3b1\/SAP155 at Thr434 , a novel in\u00a0vivo phosphorylation site","first-page":"1","volume":"13","author":"De Graaf","year":"2006"},{"key":"10.1016\/j.ejmech.2021.113911_bib50","series-title":"Europe PMC funders group \u03b1 -synuclein aggregation monitored by thioflavin T fluorescence assay","volume":"8","author":"W\u00f6rdehoff","year":"2018"},{"key":"10.1016\/j.ejmech.2021.113911_bib51","series-title":"A\u00a0natural product inhibits the initiation of \u03b1 -synuclein aggregation and suppresses its toxicity","author":"Perni","year":"2016"},{"key":"10.1016\/j.ejmech.2021.113911_bib52","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.13164","article-title":"Dyrk1A phosphorylates parkin at Ser-131 and negatively regulates its ubiquitin E3 ligase activity","volume":"134","author":"Im","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113911_bib53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0301-0082(01)00003-X","article-title":"Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease","volume":"65","author":"Blum","year":"2001","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113911_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a009316","article-title":"A\u00a0guide to neurotoxic animal models of Parkinson's disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejmech.2021.113911_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.brainresbull.2016.12.004","article-title":"Parkin and PINK1 functions in oxidative stress and neurodegeneration","volume":"133","author":"Barodia","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejmech.2021.113911_bib56","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/tx300171u","article-title":"Carnosic acid prevents 6-hydroxydopamine-induced cell death in SH-SY5Y cells via mediation of glutathione synthesis","volume":"25","author":"Chen","year":"2012","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113911_bib57","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s12035-016-9873-7","article-title":"Carnosic acid attenuates 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells by inducing autophagy through an enhanced interaction of parkin and Beclin1","volume":"54","author":"Lin","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.113911_bib58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuropharm.2016.04.017","article-title":"Carnosic acid protects SH-SY5Y cells against 6-hydroxydopamine-induced cell death through upregulation of parkin pathway","volume":"110","author":"Lin","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2021.113911_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0223-5234(03)00012-6","article-title":"High throughput artificial membrane permeability assay for blood\u2013brain barrier","volume":"38","author":"Di","year":"2003","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib60","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1096\/fj.07-104539","article-title":"Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome","volume":"22","author":"Liu","year":"2008","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2021.113911_bib61","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.freeradbiomed.2020.08.030","article-title":"The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation","volume":"160","author":"ju Lee","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejmech.2021.113911_bib62","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/cn5001815","article-title":"First selective dual inhibitors of tau phosphorylation and beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease","volume":"5","author":"Mariano","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.113911_bib64","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.euroneuro.2015.03.018","article-title":"Leucettine L41, a DYRK1A-preferential DYRKs\/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric A\u03b225-35 peptide administration in mice","volume":"25","author":"Naert","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejmech.2021.113911_bib65","article-title":"Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A","volume":"11","author":"Nguyen","year":"2018","journal-title":"DMM Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2021.113911_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-20984-z","article-title":"DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives","volume":"8","author":"Neumann","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113911_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/acel.13000","article-title":"Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: a potential therapeutic for Alzheimer's disease","volume":"18","author":"Melchior","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2021.113911_bib68","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.3390\/ijms16035235","article-title":"Hologram QSAR models of a series of 6-arylquinazolin-4-amine inhibitors of a New Alzheimer's disease target: dual specificity tyrosine-phosphorylation-regulated kinase-1A enzyme","volume":"16","author":"Leal","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.113911_bib69","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbrc.2004.03.019","article-title":"Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine","volume":"317","author":"Song","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.113911_bib70","doi-asserted-by":"crossref","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib71","doi-asserted-by":"crossref","first-page":"31895","DOI":"10.1074\/jbc.M110.147520","article-title":"Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells","volume":"285","author":"Park","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib72","article-title":"Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113911_bib73","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1242\/dev.066167","article-title":"Transient expression of Mnb\/dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling","volume":"138","author":"H\u00e4mmerle","year":"2011","journal-title":"Development"},{"key":"10.1016\/j.ejmech.2021.113911_bib74","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1523\/JNEUROSCI.4711-09.2010","article-title":"Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells","volume":"30","author":"Yabut","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejmech.2021.113911_bib75","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4161\/cc.29104","article-title":"The down syndrome-related protein kinase DYRK1A phosphorylates p27 Kip1and cyclin D1 and induces cell cycle exit and neuronal differentiation","volume":"13","author":"Soppa","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2021.113911_bib76","doi-asserted-by":"crossref","first-page":"33250","DOI":"10.1074\/jbc.M606147200","article-title":"Dyrk1A phosphorylates \u03b1-synuclein and enhances intracellular inclusion formation","volume":"281","author":"Eun","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113911_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2021.113911_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-018-0245-9","article-title":"Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy","volume":"13","author":"Gerson","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejmech.2021.113911_bib79","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","article-title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation","volume":"276","author":"G\u00f6ckler","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.113911_bib80","series-title":"Stabilization of \u03b1 -synuclein Oligomers Using Formaldehyde","first-page":"1","author":"Ruesink","year":"2019"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:37:04Z","timestamp":1759329424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":80,"alternative-id":["S0223523421007601"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113911","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/\u03b1-synuclein aggregation inhibitors with neuroprotective effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113911","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113911"}}